MYC and neoplasm: (114), observed that pharmacological inhibition of MYC resulted in reprogramming the tumor immune microenvironment through the release of T-cell recruiting chemokines and crosstalk of co-stimulatory immune checkpoint molecules CD40 and CD40L.